Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.85 ▼ -0.21
(-10.19%)
MKT CAP: $15.7M • VOL: 49.9K
52W L $2 52W H $17
ROARABLE / RQD
D- • 40/100
PIOTROSKI
4 / 9
SCLX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $30.3M | $56.6M | $46.7M |
| YoY Revenue Growth % | -46.5% | +21.1% | — |
| Gross Profit | $125.8M | $167.4M | — |
| Gross Margin % | 98.0% | 98.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$346.0M | -$83.4M | -$105.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$374.1M | -$72.8M | -$114.3M |
| EBITDA (Normalized) | -$345.9M | -$83.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $3.8M | $19.3M | -$20.7M |
| Capital Expenditures (CapEx) | $133.0K | $0 | — |
| Free Cash Flow (FCF) | $3.7M | $19.3M | -$20.7M |
| FCF Margin % | 12.2% | 34.2% | -44.3% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $5.0M | $3.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$207.8M | -$192.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SCLX.